3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Fibrosis
2
Colorectal Neoplasms
2
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Non-small Cell Lung Cancers
1
Neuritis
1
Mucositis
1
Hodgkin Disease
1
Erectile Dysfunction
1
Colonic Neoplasms
1
Capsular Contractures
1
Breast Neoplasms
1
Breast Cancer Female
1
Interventions
Cyclophosphamide
37
Cytarabine
27
Methotrexate
22
Dexamethasone
20
Vincristine
19
fludarabine
15
Mercaptopurine
14
Etoposide
14
Radiotherapy
12
Daunorubicin
12
Asparaginase
12
Doxorubicin
11
Prednisolone
9
Idarubicin
9
Busulfan
8
pegaspargase
7
blinatumomab
7
Peripheral Blood Stem Cell Transplantation
6
Melphalan
6
Immunotherapy, Adoptive
6
Imatinib Mesylate
6
Dasatinib
6
fludarabine phosphate
5
Prednisone
5
Methylprednisolone
5
Filgrastim
5
Whole-Body Irradiation
4
Thioguanine
4
Rituximab
4
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Precursor Cell Lymphoblastic Leukemia-Lymphoma
×
Pentoxifylline
×
Clear all
NCT02451774
2018-05-09
PTX-II
University of Guadalajara
Phase 2/3
Unknown
44 enrolled